{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:05:27Z","timestamp":1790874327278,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4109,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Pegylated interferon \u03b1 (PEG IFN-\u03b1) improves sustained virological response rates in chronic hepatitis C, but neither its role in acute hepatitis C nor the biologic basis for its action has been defined. This prospective study assessed the efficacy of PEG IFN-\u03b1 treatment in acute hepatitis C in relation to the kinetics of hepatitis C virus (HCV)-specific CD4<jats:sup>+<\/jats:sup> T cell responses during therapy and follow-up. Forty subjects with proven acute hepatitis C who received either PEG IFN-\u03b1 plus ribavirin (n = 20) or PEG IFN-\u03b1 monotherapy (n = 20) for 24 weeks in addition to 14 untreated subjects with acute hepatitis C were prospectively followed. Serum HCV RNA, HCV-specific CD4<jats:sup>+<\/jats:sup> T cell responses, and cytokine production were measured before and during therapy and at follow-up and correlated to the outcome. The sustained virological response rate was 85% with PEG IFN-\u03b1\/ribavirin combination and 80% with PEG IFN-\u03b1 monotherapy. Five untreated subjects had spontaneous recovery. The frequency, magnitude, and breadth of HCV-specific CD4<jats:sup>+<\/jats:sup> T helper 1 responses were significantly higher in treated subjects compared with untreated subjects with self-limited disease or subjects with chronic evolution. The CD4<jats:sup>+<\/jats:sup> T cell responses were maintained in subjects with sustained virological responses and self-limited disease but fluctuated in those who developed chronic infection. <jats:underline>In conclusion<\/jats:underline>, PEG IFN-\u03b1 therapy in acute hepatitis induces high rates of sustained virological response and prevents choronicity, probably through efficient early stimulation of multispecific HCV-specific CD4<jats:sup>+<\/jats:sup> T helper 1 responses. (Hepatology 2004;39:1721-1731.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.20266","type":"journal-article","created":{"date-parts":[[2004,5,27]],"date-time":"2004-05-27T20:02:27Z","timestamp":1085688147000},"page":"1721-1731","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":129,"title":["Pegylated interferon \u03b1 therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics"],"prefix":"10.1097","volume":"39","author":[{"given":"Sanaa M.","family":"Kamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens W.","family":"Rasenack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Tawil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta J.","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalifa El Sayed","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Madwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret James","family":"Koziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-32-20241201","first-page":"35","article-title":"Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.","volume":"6","year":"1999","journal-title":"J Viral Hepat"},{"key":"R2-32-20241201","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C.","volume":"132","author":"Liang","year":"2000","journal-title":"Ann Intern Med"},{"key":"R3-32-20241201","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/hep.510280636","article-title":"The natural history of hepatitis Ca quandary.","volume":"28","author":"Seeff","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R4-32-20241201","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":", Zankel D, et al. Treatment of acute hepatitis C with interferon alfa-2b.","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"R5-32-20241201","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1445-5994.1997.tb00985.x","article-title":"Interferon therapy for acute hepatitis C viral infectiona review by meta-analysis.","volume":"27","author":"Quin","year":"1997","journal-title":"Aust N Z J Med"},{"issue":"Suppl","key":"R6-32-20241201","doi-asserted-by":"crossref","first-page":"81S","DOI":"10.1007\/BF02087880","article-title":"High-dose interferon-alfa-2b treatment prevents chronicity in acute hepatitis C: a pilot study.","volume":"41","author":"Vogel","year":"1996","journal-title":"Dig Dis Sci"},{"issue":"Suppl","key":"R7-32-20241201","first-page":"341A","article-title":"Acute hepatitis C: natural course and response to antiviral treatment. Abstract.","volume":"34","author":"Gerlach","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R8-32-20241201","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0140-6736(91)91774-O","article-title":"Resolution of acute hepatitis C after therapy with natural beta interferon.","volume":"338","author":"Omata","year":"1991","journal-title":"Lancet"},{"key":"R9-32-20241201","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0168-8278(94)80246-7","article-title":"A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.","volume":"21","author":"Hwang","year":"1994","journal-title":"J Hepatol"},{"key":"R10-32-20241201","first-page":"181","article-title":"Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial.","volume":"30","author":"Calleri","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"R11-32-20241201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/jhep.2001.22112","article-title":"Acute hepatitis C.","volume":"33","author":"Orland","year":"2001","journal-title":"HEPATOLOGY"},{"issue":"Suppl 1","key":"R12-32-20241201","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C.","volume":"36","author":"Seeff","year":"2002","journal-title":"HEPATOLOGY"},{"issue":"Suppl 1","key":"R13-32-20241201","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C.","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R14-32-20241201","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R15-32-20241201","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R16-32-20241201","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C.","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N Engl J Med"},{"key":"R17-32-20241201","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"key":"R18-32-20241201","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2001.21747","article-title":"Efficacy and safety of pegylated (40-kd) interferon-2a compared with interferon-2a in noncirrhotic patients with chronic hepatitis C.","volume":"33","author":"Reddy","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R19-32-20241201","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"The Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.","volume":"34","author":"Lindsay","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R20-32-20241201","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.510300312","article-title":"Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.","volume":"30","author":"Cerny","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R21-32-20241201","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0016-5085(99)70353-7","article-title":"Recurrence of hepatitis C virus after loss of virus specific CD 4 T-cell response in acute hepatitis C.","volume":"117","author":"Gerlach","year":"1999","journal-title":"Gastroenterology"},{"key":"R22-32-20241201","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/gast.2001.27024","article-title":"Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4 () T-cell and cytokine response.","volume":"121","author":"Kamal","year":"2001","journal-title":"Gastroenterology"},{"key":"R23-32-20241201","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0168-8278(98)80146-3","article-title":"The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome.","volume":"29","author":"Lohr","year":"1998","journal-title":"J Hepatol"},{"key":"R24-32-20241201","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0016-5085(00)70217-4","article-title":"Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.","volume":"118","author":"Cramp","year":"2000","journal-title":"Gastroenterology"},{"key":"R25-32-20241201","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/gast.2002.36045","article-title":"Peginterferon alone or in combination with ribavirin enhances HCV specific CD4 T helper 1 responses in patients with chronic hepatitis C.","volume":"123","author":"Kamal","year":"2002","journal-title":"Gastroenterology"},{"key":"R26-32-20241201","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1086\/315450","article-title":"Association of hepatitis C virus-specific CD8() T cells with viral clearance in acute hepatitis C.","volume":"181","author":"Gruner","year":"2000","journal-title":"J Infect Dis"},{"key":"R27-32-20241201","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/jhep.2001.21162","article-title":"Differential CD4() and CD8() T cell responsiveness in hepatitis C virus infection.","volume":"33","author":"Chang","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R28-32-20241201","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0168-8278(03)00266-6","article-title":"Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4 T cell response with HCV-elimination.","volume":"39","author":"Schirren","year":"2003","journal-title":"J Hepatol"},{"key":"R29-32-20241201","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.288.5464.339","article-title":"The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.","volume":"288","author":"Farci","year":"2000","journal-title":"Science"},{"key":"R30-32-20241201","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1073\/pnas.052712599","article-title":"Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.","volume":"99","author":"Farci","year":"2002","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20266","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200406000-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:15:33Z","timestamp":1733055333000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200406000-00032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20266","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}